Mp16-01 Clinical Implications of Sunitinib and N-Desethyl-Sunitinib Plasma Concentrations for Treatment Outcome in Metastatic Renal Cell Carcinoma Patients

Journal of Urology - Netherlands
doi 10.1016/j.juro.2017.02.507
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2013English

Sunitinib-Associated Hypertension and Neutropenia as Efficacy Biomarkers in Metastatic Renal Cell Carcinoma Patients

British Journal of Cancer
Cancer ResearchOncology
2015English

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

Correlation of C-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib

Clinical Genitourinary Cancer
OncologyUrology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy